Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Top 5 global anti-viral products by market share in 2017 and 2024
Leading global anti-viral products by market share 2017 and 2024
This statistic displays the top 5 global anti-viral products based on their market share worldwide in 2017, and a projection for 2024. Gilead Sciences' Genvoya is expected to accumulate around 8.5 percent of the global market in anti-viral revenues by 2024. In the last years, Gilead Sciences’ Harvoni accounted for the largest share by a single drug of the world’s market share of anti-virals. Harvoni or Ledipasvir is used in the treatment of hepatitis C. This product was first marketed in October 2014. Hepatitis C is an infectious disease that can scar the liver and lead to cirrhosis.
Top 5 global anti-viral products by market share in 2017 and 2024
20172024*
---
---
---
---
---
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

June 2018

Region

Worldwide

Survey time period

as of May 2018

Supplementary notes

Market share based on revenue.
* Projected.

Leading global anti-viral products by market share 2017 and 2024
This statistic displays the top 5 global anti-viral products based on their market share worldwide in 2017, and a projection for 2024. Gilead Sciences' Genvoya is expected to accumulate around 8.5 percent of the global market in anti-viral revenues by 2024. In the last years, Gilead Sciences’ Harvoni accounted for the largest share by a single drug of the world’s market share of anti-virals. Harvoni or Ledipasvir is used in the treatment of hepatitis C. This product was first marketed in October 2014. Hepatitis C is an infectious disease that can scar the liver and lead to cirrhosis.
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Statistics on "Pharmaceutical market in Italy"
  • Market overview
The most important statistics
  • Pharmacy figures
  • Pharmaceutical expenditure
  • Pharmaceutical consumption
  • Brand name and generic drugs
  • Nonprescription drugs
  • Health supplements
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.